Zydus Cadila receives final approval from USFDA for Glycopyrrolate injection

India-based pharma giant, Zydus Cadila received final approval from USFDA for Glycopyrrolate injection that is used before surgery to decrease the volume of secretions from the mouth, lungs and stomach.

"Zydus Cadila has received final approval from the USFDA to market Glycopyrrolate injection in the strengths of 0.2 mg/mL and 0.4 mg/2 mL (0.2 mg/mL) single-dose vials and 1 mg/5 mL (0.2 mg/mL) and 4 mg/20 mL (0.2 mg/mL) Multiple-Dose Vials, (US RLD: Robinul)," said the official press release by Zydus Cadila.

Glycopyrrolate is used before surgery to decrease the volume of secretions from mouth, lungs and stomach. It can also be used either before or during surgery to maintain heart's normal beating rhythm. It is also used to counter the effects of some other medicines, which can slow heartbeat or produce excessive secretions when used during surgery.

Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of a gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated. The drug will be manufactured at the group's injectables manufacturing facility at CHL-Jarod, near Vadodara.

The group now has 324 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

ZyCoV-D, developed by Indian vaccine giant Zydus Cadila. The Ahmedabad-based pharma company announced that it received EUA from DCGI for India's second indigenous vaccine, ZyCoV-D on August 20.

It is the world's first plasmid DNA vaccine for COVID-19. ZyCoV-D is a three-dose vaccine that will be administered on day zero, day 28th and then on the 56th day. ZyCoV-D, is a needle-free vaccine administered using the PharmaJet, a needle-free applicator, which ensures painless intradermal vaccine delivery. This is for the first time that a technologically advanced vaccine has been successfully developed on the plasmid DNA platform for human use.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor